Ultragenyx Pharmaceu (RARE) 66.27 $RARE Ultragenyx to

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ultragenyx Pharmaceu (RARE) 66.27 $RARE

Ultragenyx to Present at Baird 2016 Global Healthcare Conference
GlobeNewswire - Thu Sep 01, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Baird 2016 Global Healthcare Conference on Thursday, September 8 at 10:15 am ET in New York, NY.
RARE: 66.27 (+0.35)

Ultragenyx Announces KRN23 Data Presentations at ASBMR 2016 Annual Meeting
GlobeNewswire - Tue Aug 23, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced upcoming presentations of data highlighting KRN23 for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) at the American Society for Bone and Mineral Research (ASBMR) 2016 Annual Meeting taking place September 16-19 in Atlanta, Georgia.
RARE: 66.27 (+0.35)

How These Biotech Stocks are Faring? -- bluebird bio, Sage Therapeutics, Ultragenyx Pharma, and Alder Biopharma
PR Newswire - Wed Aug 10, 7:20AM CDT
Despite regulatory concerns, M&A activities are expected to continue pushing some Biotech stocks to new highs. The industry belongs in the Healthcare sector which was up by 0.6% on Tuesday, August 09, 2016. Stock-Callers.com takes a look at today's featured companies and see how they fared at the close: bluebird bio Inc. (NASDAQ: BLUE), Sage Therapeutics Inc. (NASDAQ: SAGE), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Alder Biopharmaceuticals Inc. (NASDAQ: ALDR). Register now and get full and free access to our downloadable research reports on these stocks at:
BLUE: 49.33 (-0.01), ALDR: 32.54 (-0.43), SAGE: 36.96 (-0.21), RARE: 66.27 (+0.35)

Ultragenyx to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Aug 09, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following investor conferences:
RARE: 66.27 (+0.35)

Ultragenyx Reports Second Quarter 2016 Financial Results and Corporate Update
GlobeNewswire - Mon Aug 08, 3:08PM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended June 30, 2016.
RARE: 66.27 (+0.35)

5 Drug Stocks Reporting Q2 Earnings on Aug 8: AGN & More
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:24AM CDT
As the Q2 earnings cycle draws to a close, the overall picture that has emerged does not appear as grim as we feared.
AGN: 237.76 (+3.22), ENDP: 20.23 (-0.47), JNJ: 119.08 (-0.26), RARE: 66.27 (+0.35), KITE: 58.87 (+1.25), HZNP: 18.62 (-0.18), NVS: 78.27 (-0.50)

Ultragenyx to Host Conference Call for Second Quarter 2016 Financial Results and Corporate Update
GlobeNewswire - Mon Aug 01, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Monday, August 8, 2016 at 5pm ET to discuss second quarter 2016 financial results and provide a corporate update.
RARE: 66.27 (+0.35)

Ultragenyx Announces Completion of Enrollment in Phase 3 Study of KRN23 in Adults with X-Linked Hypophosphatemia (XLH)
GlobeNewswire - Thu Jul 28, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has completed patient enrollment in the Phase 3 study of KRN23 for the treatment of adults with X-linked hypophosphatemia (XLH). Data from the study are expected in 2017.
RARE: 66.27 (+0.35)

Ultragenyx Appoints Karah Parschauer as Executive Vice President, General Counsel
GlobeNewswire - Mon Jun 20, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has appointed Karah Parschauer as Executive Vice President, General Counsel. In this newly created role, she will be responsible for leading the company's legal, compliance, and corporate governance functions. She will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx's Chief Executive Officer, and will serve on the Executive Leadership Team.
AGN: 237.76 (+3.22), RARE: 66.27 (+0.35)

Ultragenyx and Takeda enter into a Collaboration to Develop and Commercialize Therapies for Rare Genetic Diseases
GlobeNewswire - Tue Jun 07, 6:00AM CDT
Ultragenyx to license and develop one or more product candidates from Takeda
RARE: 66.27 (+0.35)

Ultragenyx Pharmaceutical (RARE) Jumps: Stock Up 6.6%
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:45AM CDT
Ultragenyx Pharmaceutical Inc. (RARE) was a big mover last session, as the company saw its shares rise over 6% on the day.
RARE: 66.27 (+0.35), ANIP: 61.42 (+1.68)

Why These Biotech Stocks Have Been on Investors' Radar? - Juno Therapeutics, Immunomedics, Ultragenyx Pharma, and Intercept Pharma
PR Newswire - Wed May 25, 7:10AM CDT
The Biotech arena may not be in its best shape right now, but this does not mean investors are sidelining stocks in this space. Here are today's ActiveWallSt.com highlights: Juno Therapeutics Inc. (NASDAQ: JUNO), Immunomedics Inc. (NASDAQ: IMMU), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Get the free access these stocks' technical alerts by clicking below:
IMMU: 2.68 (-0.09), RARE: 66.27 (+0.35), ICPT: 146.82 (-1.49), JUNO: 29.29 (-0.29)

Ultragenyx reports 1Q loss
Automated Insights - Mon May 09, 3:25PM CDT
NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Monday reported a loss of $52.8 million in its first quarter.
RARE: 66.27 (+0.35)

Ultragenyx Reports First Quarter 2016 Financial Results and Corporate Update
GlobeNewswire - Mon May 09, 3:05PM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended March 31, 2016.
RARE: 66.27 (+0.35)

Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference
GlobeNewswire - Fri May 06, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 11, 2016 at 1:00pm PT in Las Vegas, NV.
RARE: 66.27 (+0.35)

Ultragenyx to Host Conference Call for First Quarter 2016 Financial Results and Corporate Update
GlobeNewswire - Fri Apr 29, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Monday, May 9, 2016 at 5pm ET to discuss first quarter 2016 financial results and provide a corporate update.
RARE: 66.27 (+0.35)

Ultragenyx Reports Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia
GlobeNewswire - Thu Apr 21, 7:31AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positive interim data from the Phase 2 study of KRN23 for the treatment of tumor-induced osteomalacia (TIO). Initial data from the first eight patients in the study, including one patient with epidermal nevus syndrome (ENS), demonstrated that KRN23 improved serum phosphorus levels and other bone metabolism measures. The study has been expanded to enroll approximately 15 patients, and enrollment is ongoing.
RARE: 66.27 (+0.35)

Ultragenyx and Saint Louis University's Center for World Health and Medicine Announce Research Collaboration to Advance Muscular Dystrophy Treatment
GlobeNewswire - Wed Mar 23, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Saint Louis University's (SLU) Center for World Health and Medicine, today announced that they have entered into three-year sponsored research and option agreements to collaborate on the development of small molecule therapeutics for the potential treatment of Facioscapulohumeral Muscular Dystrophy (FSHD).
RARE: 66.27 (+0.35)

Ultragenyx to Present at the Leerink Partners Annual Healthcare Conference
GlobeNewswire - Tue Feb 09, 7:00AM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the LEERINK Partners 5 Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 8:00am ET at the Waldorf Astoria in New York, NY.
RARE: 66.27 (+0.35)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 175

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 229

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 162

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 218

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading

Top 5 Most Recently Viewed Articles

Orion Corporation's Manager Transactions Highlight Executive Moves

Updated Category News Views 133

Understanding Orion Corporation's Executive Transactions Orion Corporation, a prominent player in the global pharmaceutical industry, has recently disclosed significant transactions involving its management, shedding light on financial movements that reflect company growth and strategy. Key Details on Managerial Transactions Recently, Orion Corporation reported under the...

Continue Reading
Congressman Questions SEC's 'Digital Asset Security' Definition

Updated Category News Views 150

Congressman Ritchie Torres Questions SEC's Use of Terminology Representative Ritchie Torres, a Democratic representative from New York, has recently shared his concerns about the phrase "digital asset security" as used by the U.S. Securities and Exchange Commission (SEC). He’s particularly interested in the legal basis and origins of this term. Congressional Dialogue...

Continue Reading
Investigating Claims for StubHub Investors: Your Options

Updated Category News Views 173

Investigation of Claims on Behalf of StubHub Investors Faruqi & Faruqi, LLP, a prominent name in national securities law, is currently looking into potential claims related to StubHub Holdings, Inc. (NYSE: STUB). This initiative aims to assist investors who might have faced losses due to the misleading statements made about the company's financial performance during its...

Continue Reading
Sarepta Therapeutics Faces Class Action Amid Safety Concerns

Updated Category News Views 256

Introduction to Sarepta Therapeutics Sarepta Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, particularly those associated with genetic factors. The company is well-known for its gene therapy treatments and aims to revolutionize treatment options for patients with Duchenne muscular dystrophy and similar...

Continue Reading